Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate
September
3, 2021
3 min read
This story originally appeared on ZacksForte Biosciences, Inc. FBRX announced that the mid-stage study of its lead product candidate FB-401, which is being evaluated for the treatment of atopic dermatitis, was not successful….
